{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:18:14Z","timestamp":1793744294017,"version":"4.6.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016282","name":"MEI Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017302","name":"Barbara Ann Karmanos Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA022453"],"award-info":[{"award-number":["P30 CA022453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA009531"],"award-info":[{"award-number":["CA009531"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006710","name":"Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007284","name":"School of Medicine, Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007284","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bcp.2023.115981","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T21:52:53Z","timestamp":1702158773000},"page":"115981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and\/or purine biosynthesis in vitro"],"prefix":"10.1016","volume":"220","author":[{"given":"Katie H.","family":"Hurrish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra L.","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna R.","family":"Temby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna L.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"H\u00fcttemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Polin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juiwanna","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijana H.","family":"Dzinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Boerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheath","family":"Al-Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergej N.","family":"Konoplev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Busquets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tiziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry H.","family":"Matherly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-716X","authenticated-orcid":false,"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7661","key":"10.1016\/j.bcp.2023.115981_b0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature."},{"issue":"3","key":"10.1016\/j.bcp.2023.115981_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of Relapsed\/Refractory Acute Myeloid Leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.bcp.2023.115981_b0015","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2147\/CMAR.S180724","article-title":"Evaluating venetoclax and its potential in treatment-naive acute myeloid leukemia","volume":"11","author":"Knight","year":"2019","journal-title":"Cancer Manag Res."},{"issue":"24","key":"10.1016\/j.bcp.2023.115981_b0020","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.bcp.2023.115981_b0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11523-020-00711-3","article-title":"Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond","volume":"15","author":"Choi","year":"2020","journal-title":"Target Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115981_b0030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica."},{"key":"10.1016\/j.bcp.2023.115981_b0035","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720986646","article-title":"Venetoclax-containing regimens in acute myeloid leukemia","volume":"12","author":"Aldoss","year":"2021","journal-title":"Ther Adv Hematol."},{"issue":"7","key":"10.1016\/j.bcp.2023.115981_b0040","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat Med."},{"issue":"7","key":"10.1016\/j.bcp.2023.115981_b0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bcp.2023.115981_b0050","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","author":"Bosc","year":"2021","journal-title":"Nat Cancer."},{"issue":"1","key":"10.1016\/j.bcp.2023.115981_b0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","article-title":"Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia","volume":"36","author":"Baccelli","year":"2019","journal-title":"Cancer Cell."},{"issue":"4","key":"10.1016\/j.bcp.2023.115981_b0060","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41589-021-00900-9","article-title":"Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase","volume":"18","author":"Reisman","year":"2022","journal-title":"Nat Chem Biol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115981_b0065","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J Exp Med."},{"issue":"9","key":"10.1016\/j.bcp.2023.115981_b0070","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1158\/1078-0432.CCR-17-2282","article-title":"A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia","volume":"24","author":"Pardee","year":"2018","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.bcp.2023.115981_b0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.acr.2019.01.005","article-title":"Pharmacology of ME-344, a novel cytotoxic isoflavone","volume":"142","author":"Zhang","year":"2019","journal-title":"Adv Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2023.115981_b0080","first-page":"689","article-title":"Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I)","volume":"5","author":"Lim","year":"2015","journal-title":"Am J Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2023.115981_b0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1078-0432.CCR-19-2023","article-title":"Randomized Phase 0\/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer","volume":"26","author":"Quintela-Fandino","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2023.115981_b0090","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cncr.29155","article-title":"Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors","volume":"121","author":"Bendell","year":"2015","journal-title":"Cancer."},{"issue":"31","key":"10.1016\/j.bcp.2023.115981_b0095","doi-asserted-by":"crossref","first-page":"49777","DOI":"10.18632\/oncotarget.10446","article-title":"A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia","volume":"7","author":"Jeyaraju","year":"2016","journal-title":"Oncotarget."},{"issue":"9","key":"10.1016\/j.bcp.2023.115981_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092400","article-title":"Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation","volume":"12","author":"Liu","year":"2020","journal-title":"Cancers."},{"issue":"7","key":"10.1016\/j.bcp.2023.115981_b0105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bcp.2023.115981_b0110","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med."},{"issue":"1","key":"10.1016\/j.bcp.2023.115981_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","article-title":"Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia","volume":"5","author":"Luedtke","year":"2020","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.bcp.2023.115981_b0120","first-page":"13","article-title":"Detection of mycoplasma contaminations","volume":"290","author":"Uphoff","year":"2005","journal-title":"Methods Mol Biol."},{"issue":"516","key":"10.1016\/j.bcp.2023.115981_b0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Science Translational Medicine."},{"issue":"11\u201312","key":"10.1016\/j.bcp.2023.115981_b0130","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10495-022-01756-7","article-title":"c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia","volume":"27","author":"Liu","year":"2022","journal-title":"Apoptosis."},{"issue":"6","key":"10.1016\/j.bcp.2023.115981_b0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-021-00502-7","article-title":"The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML","volume":"11","author":"Qiao","year":"2021","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.bcp.2023.115981_b0140","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/0006-2952(93)90608-Y","article-title":"Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport","volume":"46","author":"Matherly","year":"1993","journal-title":"Biochem Pharmacol."},{"issue":"14","key":"10.1016\/j.bcp.2023.115981_b0145","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1021\/jm00040a008","article-title":"Synthesis and biological activity of N omega-hemiphthaloyl-alpha, omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin","volume":"37","author":"Rosowsky","year":"1994","journal-title":"J Med Chem."},{"issue":"22","key":"10.1016\/j.bcp.2023.115981_b0150","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-10-1707","article-title":"Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia","volume":"16","author":"Xie","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2023.115981_b0155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev."},{"issue":"1","key":"10.1016\/j.bcp.2023.115981_b0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcph.1275","article-title":"Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients","volume":"59","author":"Bao","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.bcp.2023.115981_b0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chroma.2014.05.019","article-title":"Targeted profiling of polar intracellular metabolites using ion-pair-high performance liquid chromatography and -ultra high performance liquid chromatography coupled to tandem mass spectrometry: applications to serum, urine and tissue extracts","volume":"1349","author":"Michopoulos","year":"2014","journal-title":"Journal of Chromatography a."},{"issue":"23","key":"10.1016\/j.bcp.2023.115981_b0170","doi-asserted-by":"crossref","first-page":"34785","DOI":"10.18632\/oncotarget.9185","article-title":"Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget."},{"issue":"8","key":"10.1016\/j.bcp.2023.115981_b0175","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1038\/s41375-022-01614-0","article-title":"Novel mitochondria-targeting compounds selectively kill human leukemia cells","volume":"36","author":"Panina","year":"2022","journal-title":"Leukemia."},{"issue":"1","key":"10.1016\/j.bcp.2023.115981_b0180","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1038\/s41467-022-30396-3","article-title":"Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia","volume":"13","author":"Baran","year":"2022","journal-title":"Nat Commun."},{"issue":"7","key":"10.1016\/j.bcp.2023.115981_b0185","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","article-title":"Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199","volume":"28","author":"Niu","year":"2014","journal-title":"Leukemia."},{"issue":"11","key":"10.1016\/j.bcp.2023.115981_b0190","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/sj.leu.2400847","article-title":"Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia","volume":"11","author":"Lacombe","year":"1997","journal-title":"Leukemia."},{"key":"10.1016\/j.bcp.2023.115981_b0195","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","author":"Saito","year":"2010217179","journal-title":"Science Translational Medicine."},{"issue":"12","key":"10.1016\/j.bcp.2023.115981_b0200","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.bcp.2023.115981_b0205","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bmt.1702013","article-title":"Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods","volume":"24","author":"Venditti","year":"1999","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.bcp.2023.115981_b0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0885-4505(92)90056-5","article-title":"Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts","volume":"48","author":"Robinson","year":"1992","journal-title":"Biochem Med Metab Biol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115981_b0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40170-021-00241-0","article-title":"Aglycemic growth enhances carbohydrate metabolism and induces sensitivity to menadione in cultured tumor-derived cells","volume":"9","author":"Schmidt","year":"2021","journal-title":"Cancer Metab."},{"issue":"26","key":"10.1016\/j.bcp.2023.115981_b0220","doi-asserted-by":"crossref","first-page":"18454","DOI":"10.18632\/oncotarget.24862","article-title":"ONC201 kills breast cancer cells in vitro by targeting mitochondria","volume":"9","author":"Greer","year":"2018","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.bcp.2023.115981_b0225","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0021-9258(17)31261-9","article-title":"A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis","volume":"264","author":"Beardsley","year":"1989","journal-title":"J Biol Chem."},{"key":"10.1016\/j.bcp.2023.115981_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115283","article-title":"Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia","volume":"205","author":"Hege Hurrish","year":"2022","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.bcp.2023.115981_b0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7007-9-37","article-title":"A novel deconvolution method for modeling UDP-N-acetyl-D-glucosamine biosynthetic pathways based on (13)C mass isotopologue profiles under non-steady-state conditions","volume":"9","author":"Moseley","year":"2011","journal-title":"BMC Biol."},{"issue":"50","key":"10.1016\/j.bcp.2023.115981_b0240","doi-asserted-by":"crossref","first-page":"29682","DOI":"10.1074\/jbc.270.50.29682","article-title":"Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors","volume":"270","author":"Fairbanks","year":"1995","journal-title":"J Biol Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115981_b0245","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/jpet.115.229344","article-title":"Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344","volume":"358","author":"Manevich","year":"2016","journal-title":"J Pharmacol Exp Ther."},{"issue":"39","key":"10.1016\/j.bcp.2023.115981_b0250","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.2174\/1381612822666160719122626","article-title":"Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells","volume":"22","author":"Urra","year":"2016","journal-title":"Curr Pharm Des."},{"issue":"7494","key":"10.1016\/j.bcp.2023.115981_b0255","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature13110","article-title":"Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides","volume":"508","author":"Birsoy","year":"2014","journal-title":"Nature."},{"issue":"11","key":"10.1016\/j.bcp.2023.115981_b0260","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.bcp.2023.115981_b0265","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.bcp.2023.115981_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678008","article-title":"Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML","volume":"11","author":"Stockard","year":"2021","journal-title":"Frontiers in Oncology."},{"issue":"5","key":"10.1016\/j.bcp.2023.115981_b0275","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.bcp.2023.115981_b0280","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41375-021-01369-0","article-title":"Targeting leukemia-specific dependence on the de novo purine synthesis pathway","volume":"36","author":"Yamauchi","year":"2022","journal-title":"Leukemia."},{"key":"10.1016\/j.bcp.2023.115981_b0285","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3389\/fimmu.2018.01697","article-title":"Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy","volume":"9","author":"Yin","year":"2018","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115981_b0290","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell."},{"issue":"12","key":"10.1016\/j.bcp.2023.115981_b0295","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer."},{"issue":"4","key":"10.1016\/j.bcp.2023.115981_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13040467","article-title":"Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2","volume":"13","author":"Culp-Hill","year":"2023","journal-title":"Metabolites."},{"issue":"1","key":"10.1016\/j.bcp.2023.115981_b0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-021-01076-4","article-title":"Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine","volume":"14","author":"Buettner","year":"2021","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.bcp.2023.115981_b0310","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-3455","article-title":"Abstract 3455: Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance","author":"Mohanty","year":"20238373455","journal-title":"Cancer Research."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223005749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223005749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:18:07Z","timestamp":1762096687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223005749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":62,"alternative-id":["S0006295223005749"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115981","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and\/or purine biosynthesis in vitro","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115981"}}